1. Home
  2. EQV vs AURA Comparison

EQV vs AURA Comparison

Compare EQV & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EQV
  • AURA
  • Stock Information
  • Founded
  • EQV 2024
  • AURA 2007
  • Country
  • EQV United States
  • AURA United States
  • Employees
  • EQV N/A
  • AURA N/A
  • Industry
  • EQV
  • AURA Biotechnology: Pharmaceutical Preparations
  • Sector
  • EQV
  • AURA Health Care
  • Exchange
  • EQV Nasdaq
  • AURA Nasdaq
  • Market Cap
  • EQV 449.7M
  • AURA 370.1M
  • IPO Year
  • EQV 2024
  • AURA 2021
  • Fundamental
  • Price
  • EQV $10.23
  • AURA $5.23
  • Analyst Decision
  • EQV
  • AURA Strong Buy
  • Analyst Count
  • EQV 0
  • AURA 4
  • Target Price
  • EQV N/A
  • AURA $22.75
  • AVG Volume (30 Days)
  • EQV 163.7K
  • AURA 168.0K
  • Earning Date
  • EQV 01-01-0001
  • AURA 05-20-2025
  • Dividend Yield
  • EQV N/A
  • AURA N/A
  • EPS Growth
  • EQV N/A
  • AURA N/A
  • EPS
  • EQV N/A
  • AURA N/A
  • Revenue
  • EQV N/A
  • AURA N/A
  • Revenue This Year
  • EQV N/A
  • AURA N/A
  • Revenue Next Year
  • EQV N/A
  • AURA N/A
  • P/E Ratio
  • EQV $49.93
  • AURA N/A
  • Revenue Growth
  • EQV N/A
  • AURA N/A
  • 52 Week Low
  • EQV $9.88
  • AURA $4.84
  • 52 Week High
  • EQV $10.25
  • AURA $12.38
  • Technical
  • Relative Strength Index (RSI)
  • EQV N/A
  • AURA 42.97
  • Support Level
  • EQV N/A
  • AURA $4.94
  • Resistance Level
  • EQV N/A
  • AURA $6.29
  • Average True Range (ATR)
  • EQV 0.00
  • AURA 0.44
  • MACD
  • EQV 0.00
  • AURA 0.02
  • Stochastic Oscillator
  • EQV 0.00
  • AURA 21.48

About EQV EQV Ventures Acquisition Corp.

EQV Ventures Acquisition Corp is a blank check company.

About AURA Aura Biosciences Inc.

Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its lead candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.

Share on Social Networks: